Imperative Care, a medical technology company focused on treating thromboembolic disease, announced it has raised $100 million through an oversubscribed convertible note financing round to support continued growth and innovation. The financing was co-led by new investors Elevage Medical Technologies and Perceptive Advisors, alongside existing investor Catalio Capital Management. Additional participation came from Longaeva Partners and Brown Advisory, with continued backing from existing investors including Ally Bridge Group and Bain Capital Life Sciences.
As part of the investment, Evan Melrose, M.D., CEO of Elevage Medical Technologies, has joined Imperative Care’s Board of Directors, bringing decades of experience in medical technology investing and company building.
The company plans to use the proceeds to accelerate commercialization of its stroke and vascular thrombectomy portfolios, expand development of next-generation products, and support clinical evidence generation. This includes continued investment in the Telos robotic platform, an endovascular robotic system currently in development aimed at improving precision and expanding access to treatment.
Imperative Care’s technologies are designed to treat blood clots in both cerebral arteries and peripheral vasculature, and its products have been used in more than 78,000 procedures globally. The company operates in the growing market for thromboembolic disease treatment, a major cause of long-term disability in the United States.
BofA Securities and J.P. Morgan acted as joint placement agents for the financing.
KEY QUOTES
“This financing is a reflection of the strong momentum we have built and the confidence our investors, new and existing, have in our vision. We are expanding access to life-saving technologies for patients at the most critical moments of their lives, and this capital positions us to continue driving forward on that mission across stroke, vascular, and beyond.”
Fred Khosravi, Chairman And CEO Of Imperative Care
